- Home
- ELAN vs IONS Comparison
ELAN vs IONS Comparison
Compare ELAN & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ELAN | IONS |
|---|---|---|
| Founded | 1954 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.4B | 12.1B |
| IPO Year | 2018 | 1996 |
Fundamental Metrics
Financial Performance| Metric | ELAN | IONS |
|---|---|---|
| Price | $22.67 | $55.77 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 22 |
| Target Price | $27.89 | ★ $93.36 |
| AVG Volume (30 Days) | ★ 6.7M | 3.2M |
| Earning Date | 05-06-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 21.71 |
| EPS | ★ 0.22 | N/A |
| Revenue | ★ $4,715,000,000.00 | N/A |
| Revenue This Year | $8.21 | N/A |
| Revenue Next Year | $5.31 | $77.99 |
| P/E Ratio | $100.55 | ★ N/A |
| Revenue Growth | ★ 6.22 | N/A |
| 52 Week Low | $17.11 | $41.54 |
| 52 Week High | $27.98 | $86.74 |
Technical Indicators
Market Signals| Indicator | ELAN | IONS |
|---|---|---|
| Relative Strength Index (RSI) | 37.30 | 41.78 |
| Support Level | $20.64 | $50.64 |
| Resistance Level | $23.16 | $57.48 |
| Average True Range (ATR) | 1.16 | 1.89 |
| MACD | -0.45 | 1.03 |
| Stochastic Oscillator | 21.62 | 77.96 |
Price Performance
Historical ComparisonAbout ELAN Elanco Animal Health Incorporated
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, poultry, and swine production.
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).